Comments for BioMed News Bytes: BioCryst, Antigenics, Exelixis, Impax, Cel-Sci at http://www.biomedreports.com , comment 1 to 1 out of 1 comments http://www.biomedreports.com Wed, 08 Feb 2012 18:24:09 +0100 FeedCreator 1.7.3 http://www.biomedreports.com/2009102614931/biomed-news-bytes-biocryst-antigenics-exelixis-impax-cel-sci.html#comment-1253 Mike, In regards to Antigenics, you mentioned at Seeking Alpha that Oncophage failed two Phase III trials in the past. Is this a different study? Thanks "On 10/26/09, Antigenics (NASDAQ: AGEN) reported updated Phase 2 data for Oncophage (vitespen) in the treatment of recurrent, high-grade glioma" - pablo regen Mon, 26 Oct 2009 09:52:02 +0100